High glucose concentration induces endothelial cell proliferation by regulating cyclin-D2-related miR-98

Journal of Cellular and Molecular Medicine

Volumn 20, Issue 6, 2016, Pages 1159-1169

  Li, Xin Xin ^a   Liu, Yue Mei ^a   Li, You Jie ^a   Xie, Ning ^b   Yan, Yun Fei ^a   Chi, Yong Liang ^c   Zhou, Ling ^a   Xie, Shu Yang ^a   Wang, Ping Yu ^a  

^a BINZHOU MEDICAL UNIVERSITY   (China)

^b YANTAISHAN HOSPITAL   (China)

^c Shandong China Traditional Medical Affiliated Hospital   (China)

Author keywords

Cell proliferation; Cyclin D2; Gene expression; MiR 98; Type 2 diabetes

Indexed keywords

CASPASE 9; CYCLIN D2; GLUCOSE; MICRORNA; MICRORNA 98; PROTEIN BAX; PROTEIN BCL 2; RETINOBLASTOMA BINDING PROTEIN 1; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; MIRN98 MICRORNA-98, RAT; RETINOBLASTOMA PROTEIN;

3' UNTRANSLATED REGION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; APOPTOSIS; ARTICLE; CELL CYCLE; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIUM CELL; FLOW CYTOMETRY; GENE EXPRESSION; GENETIC TRANSFECTION; IMMUNOFLUORESCENCE TEST; MALE; MOLECULAR CLONING; MTT ASSAY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; UPREGULATION; WESTERN BLOTTING; ANIMAL; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHOSPHORYLATION; SPRAGUE DAWLEY RAT;

3' UNTRANSLATED REGIONS; ANIMALS; AORTA; APOPTOSIS; BASE SEQUENCE; CELL PROLIFERATION; CYCLIN D2; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION; GLUCOSE; MALE; MICRORNAS; PHOSPHORYLATION; RATS, SPRAGUE-DAWLEY; RETINOBLASTOMA PROTEIN;

EID: 84957998821     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12765     Document Type: Article

References (44)

1. Das UN, Rao AA. Gene expression profile in obesity and type 2 diabetes mellitus. Lipids Health Dis. 2007; 6: 35.
2. Daneman D. Type 1 diabetes. Lancet. 2006; 367: 847-58.
3. Brownlee M. Preventing kidney cell suicide. Nat Med. 2007; 13: 1284-5.
4. Cohen G, Riahi Y, Alpert E, et al. The roles of hyperglycaemia and oxidative stress in the rise and collapse of the natural protective mechanism against vascular endothelial cell dysfunction in diabetes. Arch Physiol Biochem. 2007; 113: 259-67.
5. Kehler DS, Stammers AN, Susser SE, et al. Cardiovascular complications of type 2 diabetes in youth. Biochem Cell Biol. 2014; 7: 1-15.
6. Lee CM, Huxley RR, Lam TH, et al. Prevalence of diabetes mellitus and population attributable fractions for coronary heart disease and stroke mortality in the WHO South-East Asia and Western Pacific regions. Asia Pac J Clin Nutr. 2007; 16: 187-92.
7. Aronson D, Rayfield EJ. How hyperglycemia promotes atherosclerosis: molecular mechanisms. Cardiovasc Diabetol. 2002; 1: 1.
8. Krychtiuk KA, Kastl SP, Speidl WS, et al. Inflammation and coagulation in atherosclerosis. Hamostaseologie. 2013; 33: 269-82.
9. Croce K, Libby P. Intertwining of thrombosis and inflammation in atherosclerosis. Curr Opin Hematol. 2007; 14: 55-61.
10. Kou B, Zhang J, Singer DR. Effects of cyclic strain on endothelial cell apoptosis and tubulogenesis are dependent on ROS production via NAD(P)H subunit p22phox. Microvasc Res. 2009; 77: 125-33.
11. Liu WF, Nelson CM, Tan JL, et al. Cadherins, RhoA, and Rac1 are differentially required for stretch-mediated proliferation in endothelial versus smooth muscle cells. Circ Res. 2007; 101: e44-52.
12. Shibuya M. Vascular endothelial growth factor (VEGF)-Receptor2: its biological functions, major signaling pathway, and specific ligand VEGF-E. Endothelium. 2006; 13: 63-9.
13. Bergsagel PL, Kuehl WM. Critical roles for immunoglobulin translocations and Cyclin D dysregulation in multiple myeloma. Immunol Rev. 2003; 194: 96-104.
14. Braun-Dullaeus RC, Mann MJ, Sedding DG, et al. Cell cycle-dependent regulation of smooth muscle cell activation. Arterioscler Thromb Vasc Biol. 2004; 24: 845-50.
15. Dzau VJ, Braun-Dullaeus RC, Sedding DG. Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. Nat Med. 2002; 8: 1249-56.
16. Moon CY, Ku CR, Cho YH, et al. Protocatechuic aldehyde inhibits migration and proliferation of vascular smooth muscle cells and intravascular thrombosis. Biochem Biophys Res Commun. 2012; 423: 116-21.
17. Villeneuve LM, Kato M, Reddy MA, et al. Enhanced levels of microRNA-125b in vascular smooth muscle cells of diabetic db/db mice lead to increased inflammatory gene expression by targeting the histone methyltransferase Suv39h1. Diabetes. 2010; 59: 2904-15.
18. He J, Xu Q, Jing Y, et al. Reactive oxygen species regulate ERBB2 and ERBB3 expression via miR-199a/125b and DNA methylation. EMBO Rep. 2012; 13: 1116-22.
19. Saba R, Sorensen DL, Booth SA. MicroRNA-146a: a dominant, negative regulator of the innate immune response. Front Immunol. 2014; 5: 578.
20. Corral-Fernandez NE, Salgado-Bustamante M, Martinez-Leija ME, et al. Dysregulated miR-155 expression in peripheral blood mononuclear cells from patients with type 2 diabetes. Exp Clin Endocrinol Diabetes. 2013; 121: 347-53.
21. Balasubramanyam M, Aravind S, Gokulakrishnan K, et al. Impaired miR-146a expression links subclinical inflammation and insulin resistance in Type 2 diabetes. Mol Cell Biochem. 2011; 351: 197-205.
22. Karolina DS, Armugam A, Tavintharan S, et al. MicroRNA 144 impairs insulin signaling by inhibiting the expression of insulin receptor substrate 1 in type 2 diabetes mellitus. PLoS ONE. 2011; 6: e22839.
23. Zhang C, Chi YL, Wang PY, et al. miR-511 and miR-1297 inhibit human lung adenocarcinoma cell proliferation by targeting oncogene TRIB2. PLoS ONE. 2012; 7: e46090.
24. Wang PY, Li YJ, Zhang S, et al. Regulating A549 cells growth by ASO inhibiting miRNA expression. Mol Cell Biochem. 2010; 339: 163-71.
25. Wang PY, Sun YX, Zhang S, et al. Let-7c inhibits A549 cell proliferation through oncogenic TRIB2 related factors. FEBS Lett. 2013; 587: 2675-81.
26. Matsumoto T, Noguchi E, Kobayashi T, et al. Mechanisms underlying the chronic pioglitazone treatment-induced improvement in the impaired endothelium-dependent relaxation seen in aortas from diabetic rats. Free Radic Biol Med. 2007; 42: 993-1007.
27. Malumbres M, Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer. 2001; 1: 222-31.
28. Angelis E, Garcia A, Chan SS, et al. A Cyclin D2-Rb pathway regulates cardiac myocyte size and RNA polymerase III after biomechanical stress in adult myocardium. Circ Res. 2008; 102: 1222-9.
29. Chen Z, Liu G, Xiao Y, et al. Adrenomedullin22-52 suppresses high-glucose-induced migration, proliferation, and tube formation of human retinal endothelial cells. Mol Vis. 2014; 20: 259-69.
30. Wang D, Wang L, Gu J, et al. Scutellarin inhibits high glucose-induced and hypoxia-mimetic agent-induced angiogenic effects in human retinal endothelial cells through reactive oxygen species/hypoxia-inducible factor-1alpha/vascular endothelial growth factor pathway. J Cardiovasc Pharmacol. 2014; 64: 218-27.
31. Liu SY, Yuan Q, Li XH, et al. Role of vascular peroxidase 1 in senescence of endothelial cells in diabetes rats. Int J Cardiol. 2015; 197: 182-91.
32. Floris I, Descamps B, Vardeu A, et al. Gestational diabetes mellitus impairs fetal endothelial cell functions through a mechanism involving microRNA-101 and histone methyltransferase enhancer of zester homolog-2. Arterioscler Thromb Vasc Biol. 2015; 35: 664-74.
33. Kozar K, Ciemerych MA, Rebel VI, et al. Mouse development and cell proliferation in the absence of D-Cyclins. Cell. 2004; 118: 477-91.
34. Ando K, Ajchenbaum-Cymbalista F, Griffin JD. Regulation of G1/S transition by Cyclins D2 and D3 in hematopoietic cells. Proc Natl Acad Sci USA. 1993; 90: 9571-5.
35. Dowdy SF, Hinds PW, Louie K, et al. Physical interaction of the retinoblastoma protein with human D Cyclins. Cell. 1993; 73: 499-511.
36. Schang LM. The cell cycle, Cyclin-dependent kinases, and viral infections: new horizons and unexpected connections. Prog Cell Cycle Res. 2003; 5: 103-24.
37. Johnson DG, Walker CL. Cyclins and cell cycle checkpoints. Annu Rev Pharmacol Toxicol. 1999; 39: 295-312.
38. Sun X, Belkin N, Feinberg MW. Endothelial microRNAs and atherosclerosis. Curr Atheroscler Rep. 2013; 15: 372.
39. Loyer X, Potteaux S, Vion AC, et al. Inhibition of microRNA-92a prevents endothelial dysfunction and atherosclerosis in mice. Circ Res. 2014; 114: 434-43.
40. Creemers EE, Tijsen AJ, Pinto YM. Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease? Circ Res. 2012; 110: 483-95.
41. Kota J, Chivukula RR, O'Donnell KA, et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell. 2009; 137: 1005-17.
42. Yadav S, Pandey A, Shukla A, et al. miR-497 and miR-302b regulate ethanol-induced neuronal cell death through BCL2 protein and Cyclin D2. J Biol Chem. 2011; 286: 37347-57.
43. Wang J, Dan G, Shangguan T, et al. miR-198 represses the proliferation of HaCaT cells by targeting Cyclin D2. Int J Mol Sci. 2015; 16: 17018-28.
44. Pan WK, Li P, Guo ZT, et al. Propranolol induces regression of hemangioma cells via the down-regulation of the PI3K/Akt/eNOS/VEGF pathway. Pediatr Blood Cancer. 2015; 62: 1414-20.